Author

E. López-Miranda

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.

CLINICAL TRIAL REGISTRATION www.clinicaltrials.gov identifier is NCT06382948; EU Clinical Trials identifier is EUCT 2024-512926-27-00.

J. Pérez-García, A. Llombart-Cussac, E. López-Miranda et al. · Future Oncology · 0 citations

Open access Oct 2026

Improvement of steatohepatitis during therapy with olaparib in metastatic BRCA1-mutated breast cancer: A case report suggesting new opportunities of PARP inhibitors

Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly diagnosed in patients with metastatic breast cancer (mBC). Poly(ADP-ribose)polymerase inhibitors (PARPi) improve outcomes in BRCA-mutated mBC by blocking DNA-repair mechanisms. Preclinical studies suggest that PARPi may also benefit MASLD by r...

M. Gion, Diego Burgos-Santamaría, Luis Téllez et al. · npj Gut and Liver · 0 citations